The ENETS (European Neuroendocrine Tumor Society) Consensus Guidelines suggest measuring urinary 5-HIAA and serum CgA in all patients with NETs, both as part of the diagnostic process and during follow-up [47]. The gene discussed is CGA; the disease is neoplasm.